文献速递复苏、休克与脓毒症

辅助血管加压药与成人脓毒性休克短期死亡率:系统评价与荟萃分析

ADJUNCTIVE VASOPRESSORS AND SHORT-TERM MORTALITY IN ADULTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS.
PubMed 文献 · Shock · 2025-02-07
一句话结论在成人脓毒性休克中,辅助血管加压药可能降低短期死亡风险(RR 0.92,95%CI 0.85-1.00,低确定性)并可能降低肾脏替代治疗风险(RR 0.92,95%CI 0.84-1.01,中等确定性),但可能增加数字/外周缺血风险(RR 2.44,95%CI 1.17-5.10,低确定性)。

该系统评价与荟萃分析检索了MEDLINE、Embase和Cochrane对照试验中心注册库(自建库至2023年6月7日),纳入17项随机临床试验共3813例成人脓毒性休克患者,比较在标准治疗血管加压药基础上加用血管加压素类似物、血管紧张素II、亚甲蓝、羟钴胺或儿茶酚胺类似物的辅助治疗与标准治疗。主要终点为短期死亡率(28-30天或ICU出院时或之前)。结果显示辅助血管加压药可能降低短期死亡风险(RR 0.92,95%CI 0.85-1.00,低确定性)并可能降低肾脏替代治疗风险(RR 0.92,95%CI 0.84-1.01,中等确定性),但可能增加数字/外周缺血风险(RR 2.44,95%CI 1.17-5.10,低确定性)和静脉血栓栓塞风险(RR 16.48,95%CI 0.96-283.17,低确定性,1项试验321例)。作者指出,在美国脓毒性休克中辅助血管加压药的使用率与支持有利死亡率-风险比的低证据确定性不相称。

要点

  • 在成人脓毒性休克中,辅助血管加压药可能降低短期死亡风险(RR 0.92,95%CI 0.85-1.00,低确定性,17项试验3618例)。
  • 辅助血管加压药可能降低肾脏替代治疗风险(RR 0.92,95%CI 0.84-1.01,中等确定性,8项试验2408例)。
  • 辅助血管加压药可能增加数字/外周缺血风险(RR 2.44,95%CI 1.17-5.10,低确定性,9项试验2981例)。
  • 辅助血管加压药可能增加静脉血栓栓塞风险(RR 16.48,95%CI 0.96-283.17,低确定性,1项试验321例)。
  • 低偏倚风险试验的短期死亡合并估计(RR 0.95,95%CI 0.87-1.05)与存在一些担忧或高偏倚风险试验(RR 0.82,95%CI 0.69-0.97)存在差异的证据(交互作用P=0.13)。

适用人群与场景

  • 成人脓毒性休克患者,纳入比较辅助血管加压药(血管加压素类似物、血管紧张素II、亚甲蓝、羟钴胺或儿茶酚胺类似物)与标准治疗血管加压药的随机临床试验。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,纳入17项随机临床试验,共3813例参与者。
  • 主要终点短期死亡率(28-30天或ICU出院时或之前):辅助血管加压药相比标准治疗可能降低短期死亡风险(RR 0.92,95%CI 0.85-1.00,低确定性,17项试验3618例)。
  • 次要终点肾脏替代治疗:辅助血管加压药可能降低肾脏替代治疗风险(RR 0.92,95%CI 0.84-1.01,中等确定性,8项试验2408例)。
  • 次要终点数字/外周缺血:辅助血管加压药可能增加数字/外周缺血风险(RR 2.44,95%CI 1.17-5.10,低确定性,9项试验2981例)。
  • 次要终点静脉血栓栓塞:辅助血管加压药可能增加静脉血栓栓塞风险(RR 16.48,95%CI 0.96-283.17,低确定性,1项试验321例)。
  • 亚组分析:低偏倚风险试验的短期死亡合并估计为RR 0.95(95%CI 0.87-1.05),存在一些担忧或高偏倚风险试验为RR 0.82(95%CI 0.69-0.97),交互作用P=0.13。
  • 敏感性分析和亚组分析显示结果稳健。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入随机临床试验。
  • 证据确定性采用GRADE评估:短期死亡率低确定性,肾脏替代治疗中等确定性,数字/外周缺血低确定性,静脉血栓栓塞低确定性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在成人脓毒性休克中,辅助血管加压药可能降低短期死亡风险(RR 0.92,95%CI 0.85-1.00,低确定性)并可能降低肾脏替代治疗风险(RR 0.92,95%CI 0.84-1.01,中等确定性),但可能增加数字/外周缺血风险(RR 2.44,95%CI 1.17-5.10,低确定性)和静脉血栓栓塞风险(RR 16.48,95%CI 0.96-283.17,低确定性)。
  • 作者指出,在美国脓毒性休克中辅助血管加压药的使用率与支持有利死亡率-风险比的低证据确定性不相称。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Adjunctive vasopressors are added to norepinephrine in one-third of adults with septic shock in the United States. However, effectiveness of this approach is unclear, and treatment recommendations are based on indirect evidence. We sought to synthesize the direct evidence for adjunctive vasopressor administration in adults with septic shock. Methods: We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from inception to June 7, 2023. We included randomized clinical trials of adults with septic shock comparing adjunctive treatment with a vasopressin analogue, angiotensin II, methylene blue, hydroxocobalamin, or catecholamine analog to standard care vasopressors. The primary outcome was short-term mortality (at or before 28-30 days or intensive care discharge). Secondary outcomes included kidney replacement therapy, digital/peripheral ischemia, and venous thromboembolism. Random-effects meta-analyses were conducted to derive risk ratios (RRs) and 95% CIs. The certainty of the evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation. Results: Of 6,763 records, 17 trials (3,813 participants) were included. Compared with standard care, adjunctive vasopressor administration may reduce short-term mortality risk (RR, 0.92 [95% CI, 0.85-1.00], low certainty, 17 trials [3618 participants]) and likely reduces kidney replacement therapy receipt (RR, 0.92 [95% CI, 0.84-1.01], moderate certainty, eight trials [2,408 participants]). Adjunctive vasopressor treatment may increase risk of digital/peripheral ischemia (RR, 2.44 [95% CI, 1.17-5.10], low certainty, nine trials [2,981 participants]) and venous thromboembolism (RR, 16.48 [95% CI, 0.96-283.17], low certainty, one trial [321 participants]). There was some evidence that the pooled estimate for short-term mortality was different (interaction P = 0.13) for trials adjudicated as low risk of bias (RR, 0.95 [95% CI, 0.87-1.05]) compared with trials adjudicated as some concerns or high risk of bias (RR, 0.82 [95% CI, 0.69-0.97]). The findings were robust to multiple sensitivity and subgroup analyses. Conclusions: In adults with septic shock, adjunctive vasopressors may lower short-term death risk and likely lower kidney replacement therapy risk, but may increase risk of adverse effects. In the United States, adjunctive vasopressor use prevalence in septic shock is disconnected from the low evidence certainty for a favorable mortality-to-risk profile.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Bauer SR, Wieruszewski PM, Bissell Turpin BD, et al. ADJUNCTIVE VASOPRESSORS AND SHORT-TERM MORTALITY IN ADULTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS. Shock. 2025. PMID: 39965613. doi:10.1097/SHK.0000000000002558

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。